ClinicalTrials.gg
CompletedNCT01302691Updated Mar 15, 2019Results posted

MK-0954E Study in Participants With Hypertension (MK-0954E-357)

A Phase 3 interventional study of losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E) and Losartan potassium in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-15.

Primary conditionEssential HypertensionRegistry: HypertensionReclassifiedWhy we changed it
Registry
Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Essential Hypertension
Why
  1. The study's title name Essential Hypertension, a narrower term within Hypertension.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
327
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing losartan in Essential Hypertension — none open to participants now, none under way, none of them phase 3. Losartan · Essential Hypertension.

Enrollment
5th of 10
327 · median 284
Started
2011
with 1 other
Phase 3
5 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
1 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing losartan in Essential Hypertension, this one is the 5th largest by enrollment, is one of 2 that started in 2011, is one of 5 in phase 3, and was the 6th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 10 studies testing losartan in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing losartan in Essential Hypertension as a file.
02

Study summary

This study is being done to evaluate the efficacy, safety, and tolerability of losartan potassium 50 mg (L50) + hydrochlorothiazide 12.5 mg (H12.5) + amlodipine besylate 5 mg (A5) (MK-0954E). The primary hypothesis is that L50/H12.5/A5 is more effective in lowering mean trough sitting diastolic blood pressure (SiDBP) after 8 weeks of treatment compared to L50+A5 in Japanese participants with essential hypertension who are not adequately controlled following an 8-week treatment with filter period study drug (L50+A5).

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Essential hypertension
  • Uncontrolled hypertension
  • Antihypertensive agents
  • Blood pressure
04

In context

Essential Hypertension Reclassified

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

This study's enrollment of 327 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a diagnosis of essential hypertension.
  • Participant is being treated with single or dual treatment for hypertension and will be able to discontinue the prior antihypertensive medication.
  • Participant has a mean trough SiDBP of ≥ 90 mmHg and \< 110 mmHg.
  • Participant has a mean trough SiSBP of ≥ 140 mmHg and \< 200 mmHg.
  • Participant has no abnormality at screening visit.

Exclusion criteria

Exclusion criteria

  • Participant is currently taking > 2 antihypertensive medications.
  • Participant has a history of significant multiple and/or severe allergies to ingredients of Nu-Lotan or Preminent, amlodipine or dihydropyridine drug, and thiazide drug or related drug (i.e., sulfonamide-containing "chlortalidone" medicines).
  • Participant is, at the time of signing , a user of recreational or illicit drugs or has had a recent history within the last year of drug or alcohol abuse or dependence.
  • Participant is pregnant or breastfeeding, or expecting to conceive OR the pregnancy test is positive at screening visit (Visit 1).
  • Participant is currently participating or has participated in a study with an compound or device within 30 days of signing informed consent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
327 participants (actual)

Study arms

  • Experimental
    L50/H12.5/A5

    Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.

    Drug: losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E) · Drug: Placebo to losartan potassium · Drug: Placebo to amlodipine besylate

  • Active comparator
    L50 + A5

    Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.

    Drug: Losartan potassium · Drug: Amlodipine besylate · Drug: Placebo to MK-0954E

Interventions

  • Druglosartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)

    Drug pages: Losartan · Hydrochlorothiazide · Amlodipine

    One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.

  • One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.

  • One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.

  • DrugPlacebo to MK-0954E

    One tablet, containing placebo, orally, once daily, for 8 weeks.

  • DrugPlacebo to losartan potassium

    One tablet, containing placebo, orally, once daily, for 8 weeks.

  • DrugPlacebo to amlodipine besylate

    One capsule, containing placebo, orally, once daily, for 8 weeks.

07

What researchers measure

Primary outcomes

  1. Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP)

    Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.

    Time frame: Baseline and Week 8

  2. Percentage of Participants Who Experience ≥1 Adverse Event (AE)

    An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 10-week treatment and follow-up period were summarized by study drug received.

    Time frame: up to 14 days after last dose of study drug (up to 10 weeks)

  3. Percentage of Participants Who Experience ≥1 Drug-related AE

    An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received.

    Time frame: up to 14 days after last dose of study drug (up to 10 weeks)

  4. Percentage of Participants Who Experience ≥1 Serious Adverse Event (SAE)

    An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 10-week treatment and follow-up period were summarized by study drug received.

    Time frame: up to 14 days after last dose of study drug (up to 10 weeks)

  5. Percentage of Participants Who Experience ≥1 Drug-related SAE

    An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received

    Time frame: up to 14 days after last dose of study drug (up to 10 weeks)

  6. Percentage of Participants Who Had Study Drug Stopped Due to an AE

    An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm

    Time frame: up to 8 weeks

Secondary outcomes

  1. Change in Mean Trough Sitting Systolic Blood Pressure (SiSBP)

    Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.

    Time frame: Baseline and Week 8

08

Results

Posted Jan 27, 2017

Participant flow

Participant flow — Overall Study
MilestoneL50/H12.5/A5L50 + A5
Started164163
Completed154157
Not completed106
Withdrew: Adverse event20
Withdrew: Death01
Withdrew: Lost to follow-up10
Withdrew: Blood pressure/potassium criteria met64
Withdrew: Physician decision01
Withdrew: Protocol violation10

Outcome measures

PrimaryChange in Mean Trough Sitting Diastolic Blood Pressure (SiDBP)

Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mmHg
Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP)
mmHgL50/H12.5/A5L50 + A5
Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP)-9.1 (-10.2 to -7.9)-8.0 (-9.1 to -6.8)
Statistical analysis
  • L50/H12.5/A5 vs L50 + A5 · Constrained Longitudinal Data Analysis · p = 0.205 · Difference in least squares means: -1.1 · 95% CI -2.7 to 0.6Model includes treatment group, time point, and the interaction of time by treatment with restriction of same baseline mean across treatment groups
PrimaryPercentage of Participants Who Experience ≥1 Adverse Event (AE)

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 10-week treatment and follow-up period were summarized by study drug received.

Time frame:
up to 14 days after last dose of study drug (up to 10 weeks)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience ≥1 Adverse Event (AE)
Percentage of ParticipantsL50/H12.5/A5L50 + A5
Percentage of Participants Who Experience ≥1 Adverse Event (AE)30.528.8
PrimaryPercentage of Participants Who Experience ≥1 Drug-related AE

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received.

Time frame:
up to 14 days after last dose of study drug (up to 10 weeks)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience ≥1 Drug-related AE
Percentage of ParticipantsL50/H12.5/A5L50 + A5
Percentage of Participants Who Experience ≥1 Drug-related AE11.63.7
PrimaryPercentage of Participants Who Experience ≥1 Serious Adverse Event (SAE)

An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 10-week treatment and follow-up period were summarized by study drug received.

Time frame:
up to 14 days after last dose of study drug (up to 10 weeks)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience ≥1 Serious Adverse Event (SAE)
Percentage of ParticipantsL50/H12.5/A5L50 + A5
Percentage of Participants Who Experience ≥1 Serious Adverse Event (SAE)0.60.6
PrimaryPercentage of Participants Who Experience ≥1 Drug-related SAE

An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received

Time frame:
up to 14 days after last dose of study drug (up to 10 weeks)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience ≥1 Drug-related SAE
Percentage of ParticipantsL50/H12.5/A5L50 + A5
Percentage of Participants Who Experience ≥1 Drug-related SAE0.00.0
PrimaryPercentage of Participants Who Had Study Drug Stopped Due to an AE

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm

Time frame:
up to 8 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Study Drug Stopped Due to an AE
Percentage of ParticipantsL50/H12.5/A5L50 + A5
Percentage of Participants Who Had Study Drug Stopped Due to an AE1.20.0
SecondaryChange in Mean Trough Sitting Systolic Blood Pressure (SiSBP)

Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mmHg
Change in Mean Trough Sitting Systolic Blood Pressure (SiSBP)
mmHgL50/H12.5/A5L50 + A5
Change in Mean Trough Sitting Systolic Blood Pressure (SiSBP)-13.4 (-15.2 to -11.6)-10.2 (-12.0 to -8.4)
Statistical analysis
  • L50/H12.5/A5 vs L50 + A5 · Constrained Longitudinal Data Analysis · p = 0.011 · Difference in least squares means: -3.2 · 95% CI -5.7 to -0.8Model includes treatment group, time point, and the interaction of time by treatment with restriction of same baseline mean across treatment groups

Adverse events

Collected over up to 2 weeks after last dose of study drug (up to 10 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
L50/H12.5/A5—1/164 (0.6%)11/164 (6.7%)
L50 + A5—1/163 (0.6%)15/163 (9.2%)
Most frequent serious events
Most frequent serious events
EventL50/H12.5/A5L50 + A5
Sudden cardiac deathGeneral disorders0/1641/163
Clavicle fractureInjury, poisoning and procedural complications1/1640/163
Rib fractureInjury, poisoning and procedural complications1/1640/163
PneumothoraxRespiratory, thoracic and mediastinal disorders1/1640/163
Most frequent other events
Most frequent other events
EventL50/H12.5/A5L50 + A5
NasopharyngitisInfections and infestations11/16415/163

Baseline characteristics

Age, Continuous
Age, Continuous(years)L50/H12.5/A5L50 + A5Total
Mean54.9 ± 9.455.4 ± 10.155.2 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)L50/H12.5/A5L50 + A5Total
Female334174
Male131122253
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • Rakugi H, Tsuchihashi T, Shimada K, Numaguchi H, Nishida C, Yamaguchi H, Shirakawa M, Azuma K, Fujita KP. Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. Clin Exp Hypertens. 2015;37(3):260-6. doi: 10.3109/10641963.2014.954712. Epub 2014 Oct 1. PubMed 25271811 ↗
  • Rakugi H, Tsuchihashi T, Shimada K, Numaguchi H, Nishida C, Yamaguchi H, Shirakawa M, Azuma K, Fujita KP. Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. Hypertens Res. 2015 May;38(5):329-35. doi: 10.1038/hr.2015.3. Epub 2015 Feb 26. PubMed 25716649 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2011 to primary completion in Apr 2012, 15 months.

Results were first posted in Jan 2017, 4 years 9 months after primary completion.

Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's 15 months is close to that.

Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2011
First posted
Feb 24, 2011
StartActual
Jan 1, 2011
Primary completionActual
Apr 1, 2012
CompletionActual
Apr 1, 2012
Results first posted
Jan 27, 2017
Last update
Mar 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01302691
Responsible party
Sponsor
First posted
Feb 24, 2011
Start date
Jan 1, 2011
Primary completion
Apr 1, 2012
Completion
Apr 1, 2012
Results posted
Jan 27, 2017
Last update
Mar 15, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Losartan · Hydrochlorothiazide · Amlodipine

Start the discussion